Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 3Neuroblastoma 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Pemetrexed 8Spinal Puncture 5Specimen Handling 4Radiotherapy 4Magnetic Resonance Spectroscopy 4aflutinib 3Trastuzumab 3Bevacizumab 3trastuzumab deruxtecan 2pembrolizumab 2osimertinib 2Radiotherapy, Intensity-Modulated 2tucatinib 1toripalimab 1sintilimab 1sacituzumab govitecan 1pertuzumab 1peginterferon alfa-2b 1lorlatinib 1lenvatinib 1azeliragon 1avelumab 1adavosertib 1Temozolomide 1Referral and Consultation 1Radiosurgery 1Radiation 1Probability 1Physical Examination 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Carcinomatosis × lorlatinib × 1 year × Clear all
NCT06282874 2026-04-09

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Guangdong Association of Clinical Trials

Phase 4 Active not recruiting
41 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡